NASDAQ:TGTX - TG Therapeutics Stock Price, Price Target & More

$14.40 -0.30 (-2.04 %)

(As of 04/20/2018 04:00 PM ET)

Previous Close$14.40

Today's Range$14.35 - $14.80

52-Week Range$7.25 - $17.35

Volume630,587 shs

Average Volume1.10 million shs

Market Capitalization$1.11 billion

P/E Ratio-7.54

Dividend YieldN/A

Beta1.2

About TG Therapeutics (NASDAQ:TGTX)

TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia. The company also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies. In addition, it develops a pre-clinical program to develop interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors; bromodomain and extra terminal (BET) inhibitor program for cancer treatment; and anti-PD-L1 and anti-GITR antibody research programs that are in pre-clinical development stage in the field of hematological malignancies. The company has license agreements with LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, and Ildong Pharmaceutical Co. Ltd. for the development and commercialization of TG-1101 (ublituximab); Rhizen Pharmaceuticals, SA for the development and commercialization of TGR-1202; Ligand Pharmaceuticals Incorporated for the development and commercialization of IRAK4 inhibitor technology; Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs; and Jubilant Biosys for the development and commercialization of BET inhibitor program. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.

Receive TGTX News and Ratings via Email

Sign-up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:TGTX

CUSIPN/A

Webwww.tgtherapeutics.com

Phone212-554-4484

Debt

Debt-to-Equity RatioN/A

Current Ratio3.34%

Quick Ratio3.34%

Price-To-Earnings

Trailing P/E Ratio-7.54

Forward P/E Ratio-8.57

P/E GrowthN/A

Sales & Book Value

Annual Sales$150,000.00

Price / Sales7,255.68

Cash FlowN/A

Price / CashN/A

Book Value$0.95 per share

Price / Book15.16

Profitability

EPS (Most Recent Fiscal Year)($1.91)

Net Income$-118,470,000.00

Net Margins-77,945.40%

Return on Equity-145.58%

Return on Assets-111.88%

Miscellaneous

Employees75

Outstanding Shares75,580,000

How to Become a New Pot Stock Millionaire

TG Therapeutics (NASDAQ:TGTX) Frequently Asked Questions

What is TG Therapeutics' stock symbol?

TG Therapeutics trades on the NASDAQ under the ticker symbol "TGTX."

How were TG Therapeutics' earnings last quarter?

TG Therapeutics, Inc (NASDAQ:TGTX) released its earnings results on Thursday, March, 8th. The biopharmaceutical company reported ($0.46) EPS for the quarter, hitting the consensus estimate of ($0.46). The biopharmaceutical company had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.04 million. TG Therapeutics had a negative net margin of 77,945.40% and a negative return on equity of 145.58%. View TG Therapeutics' Earnings History.

What price target have analysts set for TGTX?

6 brokers have issued 1 year price objectives for TG Therapeutics' shares. Their forecasts range from $23.00 to $33.00. On average, they anticipate TG Therapeutics' share price to reach $27.75 in the next twelve months. View Analyst Ratings for TG Therapeutics.

What are Wall Street analysts saying about TG Therapeutics stock?

Here are some recent quotes from research analysts about TG Therapeutics stock:

1. Raymond James analysts commented, "We are reiterating our Strong Buy rating on TG Therapeutics. At the 2018 American Association of Cancer Research (AACR) annual meeting, the company presented a poster featuring preclinical data of a BET inhibitor (TG-1601), which, based on our analysis of the data, supports clinical evaluation of this compound in combination with the company’s other pipeline products. Separately, in the PI3K delta world, Incyte presented clinical data of its PI3K delta inhibitor (INCB050465) in combination with pembrolizumab (Pembro) in solid tumors, demonstrating that PI3K delta inhibition appeared to synergize with PD-1 blockade. We view the totality of the clinical findings as great news for TG Therapeutics given that the company may have a best-in-class PI3K delta inhibitor, which could also demonstrate synergistic clinical effects when combined with a PD-1/PD-L1 inhibitor." (4/19/2018)
2. According to Zacks Investment Research, "TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York. " (2/16/2018)
3. HC Wainwright analysts commented, "TG Announces Global License Agreement With Jiangsu Hengrui Medicine for Development of Novel BTK Inhibitors TG licenses novel BTK inhibitors that demonstrate superior selectivity to BTK in comparison to ibrutinib in the preclinical setting. On the morning of January 8, TG Therapeutics announced that it has entered into an exclusive global license agreement with Jiangsu Hengrui Medicine, pursuant to which TG will obtain worldwide rights, excluding Asia but including Japan, for the development of Hengrui’s BTK inhibitor program. The program includes TG-1701 and TG-1702, both of which are orally-available, covalently-bound BTK inhibitors." (1/8/2018)

Are investors shorting TG Therapeutics?

TG Therapeutics saw a decrease in short interest in the month of March. As of March 15th, there was short interest totalling 14,021,571 shares, a decrease of 13.0% from the February 28th total of 16,118,224 shares. Based on an average daily trading volume, of 1,556,466 shares, the short-interest ratio is currently 9.0 days. Currently, 24.9% of the company's shares are short sold.

Who are some of TG Therapeutics' key competitors?

Some companies that are related to TG Therapeutics include The Medicines (MDCO), Global Blood Therapeutics (GBT), Portola Pharmaceuticals (PTLA), AnaptysBio (ANAB), Heron Therapeutics (HRTX), Corcept Therapeutics (CORT), Intercept Pharmaceuticals (ICPT), Motif (MTFB), Esperion Therapeutics (ESPR), Spectrum Pharmaceuticals (SPPI), Arena Pharmaceuticals (ARNA), Aimmune Therapeutics (AIMT), Cambrex (CBM), OPKO Health (OPK), Insmed (INSM), Phibro Animal Health (PAHC), MyoKardia (MYOK) and Madrigal Pharmaceuticals (MDGL).

Who are TG Therapeutics' key executives?

TG Therapeutics' management team includes the folowing people:

Mr. Michael S. Weiss, Exec. Chairman, Chief Exec. Officer and Pres (Age 52)
Mr. Sean A. Power CPA, Chief Financial Officer, Corp. Sec. and Treasurer (Age 36)
Jenna Bosco, Director of Investor Relations

Has TG Therapeutics been receiving favorable news coverage?

News headlines about TGTX stock have trended somewhat positive this week, according to Accern Sentiment. The research firm scores the sentiment of press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. TG Therapeutics earned a daily sentiment score of 0.19 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 46.79 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

How do I buy shares of TG Therapeutics?

Shares of TGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is TG Therapeutics' stock price today?

One share of TGTX stock can currently be purchased for approximately $14.40.

How big of a company is TG Therapeutics?

TG Therapeutics has a market capitalization of $1.11 billion and generates $150,000.00 in revenue each year. The biopharmaceutical company earns $-118,470,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. TG Therapeutics employs 75 workers across the globe.

How can I contact TG Therapeutics?

TG Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at 212-554-4484 or via email at [email protected]

MarketBeat Community Rating for TG Therapeutics (TGTX)

Community Ranking:		3.6 out of 5 ( )
Outperform Votes:		396 (Vote Outperform)
Underperform Votes:		150 (Vote Underperform)
Total Votes:		546

MarketBeat's community ratings are surveys of what our community members think about TG Therapeutics and other stocks. Vote "Outperform" if you believe TGTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TGTX will underperform the S&P 500 over the long term. You may vote once every thirty days.

TG Therapeutics (NASDAQ:TGTX) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

6 Wall Street analysts have issued ratings and price targets for TG Therapeutics in the last 12 months. Their average twelve-month price target is $27.75, suggesting that the stock has a possible upside of 92.71%. The high price target for TGTX is $33.00 and the low price target for TGTX is $23.00. There are currently 6 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	3.00	3.00	3.00	3.00
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 9 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 9 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$27.75	$27.75	$27.1875	$26.75
Price Target Upside:	92.71% upside	68.18% upside	184.69% upside	122.92% upside

TG Therapeutics (NASDAQ:TGTX) Consensus Price Target History

Price Target History for TG Therapeutics (NASDAQ:TGTX)

TG Therapeutics (NASDAQ:TGTX) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/19/2018	Raymond James	Reiterated Rating	Buy		Low
3/9/2018	B. Riley	Reiterated Rating	Buy -> Buy	$21.50 -> $27.00	Medium
1/16/2018	HC Wainwright	Reiterated Rating	Buy	$33.00	Low
10/3/2017	SunTrust Banks	Reiterated Rating	Buy	$28.00	Medium
6/17/2017	FBR & Co	Reiterated Rating	Buy		Low
6/5/2017	Jefferies Group	Reiterated Rating	Buy	$23.00	Medium
3/8/2017	Ladenburg Thalmann	Set Price Target	Buy	$30.00	Low
3/7/2017	Langenberg & Company	Boost Price Target	Positive	$28.00 -> $30.00	N/A
2/22/2017	Aegis	Initiated Coverage	Buy	$26.00	N/A
12/7/2016	Roth Capital	Set Price Target	Buy	$33.00	N/A
10/6/2016	Brean Capital	Reiterated Rating	Buy	$28.00	N/A
8/24/2016	S&P Equity Research	Lower Price Target		$7.15 -> $6.40	N/A

(Data available from 4/21/2016 forward)

TG Therapeutics (NASDAQ:TGTX) Earnings History and Estimates Chart

Earnings by Quarter for TG Therapeutics (NASDAQ:TGTX)

TG Therapeutics (NASDAQ:TGTX) Earnings Estimates

2018 EPS Consensus Estimate: ($1.97)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($0.48)	($0.48)	($0.48)
Q2 2018	1	($0.48)	($0.48)	($0.48)
Q3 2018	1	($0.50)	($0.50)	($0.50)
Q4 2018	1	($0.51)	($0.51)	($0.51)

TG Therapeutics (NASDAQ TGTX) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
3/8/2018	Q4 2017	($0.46)	($0.46)	$0.04 million	$0.04 million	View	N/A
11/8/2017	Q3 2017	($0.43)	($0.48)	$0.04 million	$0.04 million	View	N/A
8/9/2017	Q2 2017	($0.46)	($0.45)	$0.04 million	$0.04 million	View	Listen
5/5/2017	Q1 2017	($0.42)	($0.52)	$0.04 million	$0.04 million	View	N/A
3/10/2017	Q4 2016	($0.39)	($0.48)	$0.04 million	$0.04 million	View	N/A
11/7/2016	Q3	($0.31)	($0.50)	$0.04 million	$0.04 million	View	Listen
8/8/2016	Q2	($0.29)	($0.33)	$0.04 million	$0.04 million	View	N/A
5/10/2016	Q1	($0.36)	($0.28)	$0.04 million	$0.04 million	View	Listen
3/7/2016	Q4	($0.32)	($0.37)	$38.10 million	$38.10 million	View	N/A
11/9/2015	Q3	($0.34)	($0.28)	$0.04 million	$0.04 million	View	N/A
8/10/2015	Q215	($0.32)	($0.38)	$0.22 million	$0.04 million	View	Listen
5/4/2015	Q115	($0.33)	($0.39)	$0.04 million	$0.04 million	View	N/A
3/11/2015	Q414	($0.26)	($0.48)	$0.04 million	$0.04 million	View	N/A
11/10/2014	Q214	($0.32)	($0.51)	$0.04 million	$0.04 million	View	N/A
7/21/2014		($0.28)	($0.36)	$0.04 million	$0.04 million	View	N/A
5/12/2014	Q114	($0.19)	($0.25)	$0.04 million	$0.04 million	View	N/A
3/5/2014	Q413	($0.18)	($0.19)	$40.00 million	$38.10 million	View	N/A
11/11/2013	Q313	($0.22)	($0.62)	$0.03 million	$0.0381 million	View	N/A
8/1/2013	Q213	($0.16)	($0.29)		$0.04 million	View	N/A
5/13/2013	Q1 2013	($0.14)	($0.17)	$0.04 million	$0.04 million	View	N/A
3/21/2013	Q4 2012	($0.13)	($0.04)			View	N/A
11/8/2012	Q3 2012	($0.12)	($0.16)			View	N/A
11/14/2011	Q3 2011		($23.37)			View	N/A

(Earnings results data provided by Zacks Investment Research)

TG Therapeutics (NASDAQ:TGTX) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

TG Therapeutics (NASDAQ TGTX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 16.70%
Institutional Ownership Percentage: 47.33%

Insider Trading History for TG Therapeutics (NASDAQ:TGTX)

Institutional Ownership by Quarter for TG Therapeutics (NASDAQ:TGTX)

TG Therapeutics (NASDAQ TGTX) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/2/2018	Sean A Power	CFO	Sell	32,006	$8.50	$272,051.00	517,464
6/19/2017	Sean A Power	CFO	Sell	59,976	$11.09	$665,133.84	477,464
4/11/2017	William James Kennedy	Director	Sell	8,548	$10.27	$87,787.96
4/4/2017	Laurence N. Charney	Director	Sell	7,000	$11.17	$78,190.00
1/4/2017	Sean A. Power	CFO	Sell	8,816	$4.55	$40,112.80
4/18/2016	Sean A Power	CFO	Sell	10,000	$10.12	$101,200.00	466,682
1/5/2016	Sean A Power	CFO	Sell	22,790	$11.21	$255,475.90	476,682
7/8/2015	William James Kennedy	Director	Sell	17,000	$17.08	$290,360.00
7/1/2015	Sean A Power	CFO	Sell	50,054	$16.46	$823,888.84
4/2/2015	Sean A Power	CFO	Sell	23,800	$15.50	$368,900.00
1/7/2015	Sean A Power	CFO	Sell	66,401	$16.40	$1,088,976.40
1/5/2015	Sean A Power	CFO	Sell	54,057	$16.40	$886,534.80
12/16/2014	Michael S Weiss	Major Shareholder	Sell	210,618	$16.44	$3,462,559.92
12/16/2014	Sean A Power	CFO	Sell	38,041	$16.44	$625,394.04
12/11/2013	Michael Weiss	major shareholder	Buy	10,000	$3.43	$34,300.00	7,839,471

(Data available from 1/1/2013 forward)

TG Therapeutics (NASDAQ TGTX) News Headlines

Source:

Date	Headline
	TG Therapeutics (TGTX) Announces Preclinical Data Presentation on the Company’s BET Inhibitor, TG-1601, at AACR www.streetinsider.com - April 19 at 4:49 PM
	Raymond James Reiterates "Buy" Rating for TG Therapeutics (TGTX) www.americanbankingnews.com - April 19 at 11:46 AM
	TG Therapeutics, Inc. Announces Preclinical Data Presentation on the Company's BET Inhibitor, TG-1601, at the 2018 ... globenewswire.com - April 19 at 9:31 AM
	TG Therapeutics (TGTX) Stock Rating Upgraded by Zacks Investment Research www.americanbankingnews.com - April 18 at 2:58 PM
	TG Therapeutics, Inc. Announces Preclinical Data Presentation on the Company’s BET Inhibitor, TG-1601, at the 2018 American Association for Cancer Research (AACR) Annual Meeting finance.yahoo.com - April 18 at 9:35 AM
	Analysts Anticipate TG Therapeutics Inc (TGTX) Will Announce Quarterly Sales of $40,000.00 www.americanbankingnews.com - April 15 at 3:45 AM
	Q2 2018 Biotech Catalyst Watchlist: Phase 3 Clinical Trials seekingalpha.com - April 13 at 4:43 PM
	Analysts Expect TG Therapeutics Inc (TGTX) Will Post Earnings of -$0.46 Per Share www.americanbankingnews.com - April 13 at 1:10 PM
	TG Therapeutics Inc (TGTX) Receives Average Rating of "Buy" from Analysts www.americanbankingnews.com - April 11 at 5:43 PM
	BidaskClub Lowers TG Therapeutics (TGTX) to Sell www.americanbankingnews.com - April 10 at 3:25 PM
	TG Therapeutics' (TGTX) Buy Rating Reaffirmed at SunTrust Banks www.americanbankingnews.com - April 8 at 10:08 AM
	TG Therapeutics, Inc. to Present at the Needham 17th Annual Healthcare Conference finance.yahoo.com - April 3 at 9:26 AM
	TG Therapeutics (TGTX) Raised to Buy at ValuEngine www.americanbankingnews.com - April 2 at 11:28 PM
	Edited Transcript of TGTX earnings conference call or presentation 8-Mar-18 1:30pm GMT finance.yahoo.com - April 1 at 9:19 AM
	TG Therapeutics (TGTX) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow seekingalpha.com - March 30 at 9:17 AM
	$40,000.00 in Sales Expected for TG Therapeutics Inc (TGTX) This Quarter www.americanbankingnews.com - March 29 at 4:54 AM
	TG Therapeutics Inc (TGTX) Sees Large Decline in Short Interest www.americanbankingnews.com - March 29 at 2:21 AM
	The 7 Best Stocks From Each Sector of Q1 investorplace.com - March 28 at 4:38 PM
	HC Wainwright Reiterates "Buy" Rating for TG Therapeutics (TGTX) www.americanbankingnews.com - March 28 at 12:58 PM
	TG Therapeutics (TGTX) Downgraded to "Hold" at BidaskClub www.americanbankingnews.com - March 28 at 11:04 AM
	TG Therapeutics (TGTX) Stock Rating Lowered by BidaskClub www.americanbankingnews.com - March 26 at 10:59 PM
	TG Therapeutics (TGTX) Upgraded at BidaskClub www.americanbankingnews.com - March 24 at 12:28 PM
	TG Therapeutics' (TGTX) CEO Michael Weiss on Q4 2017 Results - Earnings Call Transcript seekingalpha.com - March 18 at 9:39 AM
	TG Therapeutics Inc (TGTX) Given Average Recommendation of "Buy" by Brokerages www.americanbankingnews.com - March 17 at 5:30 PM
	TG Therapeutics (TGTX) Announces Preclinical Data Presentation at AACR www.streetinsider.com - March 16 at 10:04 AM
	TG Therapeutics, Inc. Announces Preclinical Data Presentation at the 2018 American Association for Cancer Research (AACR) Annual Meeting finance.yahoo.com - March 15 at 10:19 AM
	Short Interest in TG Therapeutics Inc (TGTX) Declines By 15.0% www.americanbankingnews.com - March 12 at 1:24 AM
	TG Therapeutics (TGTX) Posts Earnings Results, Hits Estimates www.americanbankingnews.com - March 9 at 6:52 PM
	TG Therapeutics (TGTX) PT Raised to $27.00 www.americanbankingnews.com - March 9 at 9:18 AM
	TG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2017 Financial Results and Business Update finance.yahoo.com - March 8 at 10:31 AM
	TG Therapeutics, Inc. to Host Conference Call on Fourth Quarter and Year-End 2017 Financial Results and Business Update finance.yahoo.com - March 6 at 9:34 AM
	Senzar Asset Management LLC Boosts Position in TG Therapeutics Inc (TGTX) www.americanbankingnews.com - March 5 at 3:45 PM
	Zacks: Brokerages Expect TG Therapeutics Inc (TGTX) Will Announce Earnings of -$0.46 Per Share www.americanbankingnews.com - February 21 at 3:18 PM
	TG Therapeutics, Inc. Announces Publication of Clinical Data from the Phase 1 First-in-Human Trial of Umbralisib in The Lancet Oncology finance.yahoo.com - February 21 at 9:50 AM
	TG Therapeutics Inc (TGTX) Receives Average Recommendation of "Buy" from Analysts www.americanbankingnews.com - February 20 at 5:32 PM
	Protagonist Therapeutics (PTGX) and TG Therapeutics (TGTX) Head to Head Survey www.americanbankingnews.com - February 18 at 1:46 PM
	TG Therapeutics (TGTX) Upgraded at Zacks Investment Research www.americanbankingnews.com - February 16 at 7:42 PM
	Equities Analysts Set Expectations for TG Therapeutics Inc's FY2018 Earnings (TGTX) www.americanbankingnews.com - February 15 at 10:56 AM
	TG Therapeutics Inc Forecasted to Earn FY2022 Earnings of $1.12 Per Share (TGTX) www.americanbankingnews.com - February 14 at 4:12 PM
	TG Therapeutics: Further Appreciation In 2018 Likely - Seeking Alpha seekingalpha.com - February 6 at 6:25 AM
	TG Therapeutics Inc (TGTX) Expected to Post Earnings of -$0.46 Per Share www.americanbankingnews.com - February 4 at 3:20 PM
	TG Therapeutics (TGTX) Upgraded by ValuEngine to Hold www.americanbankingnews.com - February 4 at 11:46 AM
	TG Therapeutics (TGTX) Announces Updated Results from Ongoing ... - StreetInsider.com www.streetinsider.com - February 2 at 3:26 PM
	TG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of Ublituximab (TG-1101) in Patients with Multiple Sclerosis at the Third Annual ACTRIMS Forum 2018 finance.yahoo.com - February 2 at 3:26 PM
	TG Therapeutics (TGTX) Stock Rating Upgraded by BidaskClub www.americanbankingnews.com - January 30 at 8:18 AM
	TG Therapeutics Inc (TGTX) Receives Consensus Recommendation of "Buy" from Analysts www.americanbankingnews.com - January 26 at 5:38 PM
	TG Therapeutics, Inc. Announces Data Presentation at the ... - GlobeNewswire (press release) globenewswire.com - January 24 at 3:28 PM
	TG Therapeutics, Inc. Announces Data Presentation at the Upcoming Third Annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2018 finance.yahoo.com - January 24 at 9:52 AM
	TG Therapeutics Inc (TGTX) Expected to Announce Quarterly Sales of $40,000.00 www.americanbankingnews.com - January 20 at 4:56 AM
	TG Therapeutics (TGTX) Rating Reiterated by B. Riley www.americanbankingnews.com - January 17 at 1:34 PM

TG Therapeutics (NASDAQ:TGTX) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

TG Therapeutics (NASDAQ:TGTX) Income Statement, Balance Sheet and Cash Flow Statement

TG Therapeutics (NASDAQ TGTX) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff